ClinicalTrials.gg
CompletedNCT01177839Updated Nov 22, 2012

Study to Assess the Incidence of Intussusception in Children < 2 Years of Age in Singapore

An observational study in Intussusception, sponsored by GlaxoSmithKline. Completed at 5 sites in Singapore. Open to participants aged Up to 24 Months. Per ClinicalTrials.gov, last updated 2012-11-22.

Sponsored by GlaxoSmithKline · Observational

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
178
Ages
Up to 24 Months
Sex
All
01

Study summary

This prospective study aims to estimate the incidence of intussusception among children \< 2 years old through hospital-based surveillance in Singapore.

02

Conditions studied

  • Intussusception

Browse trials for

03

In context

Intussusception

31 studies on the registry are indexed under Intussusception; 6 are open to participants now.

This study's enrollment of 178 is below the median of 250 across 15 observational studies indexed under Intussusception.

Browse Intussusception studies →

Lead sponsor

GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 118 are open to participants now.

Of its 264 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 24 Months
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All subjects \< 24 months of age seen on an in- or out-patient basis with a diagnosis of intussusception during at least a one year period beginning at study start.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A male or female infant aged \< 24months at the time of diagnosis of intussusception.
  • Subject is diagnosed with definite, probable, possible, suspected intussusception during the period of at least one year beginning at study start.
  • Written obtained from the parent or guardian of the subject.

Exclusion criteria

Exclusion Criteria:

  • A male or female infant ≥ 24 months of age at the time of intussusception diagnosis.
  • The subject has had a radiographically or surgically confirmed case of intussusception prior to the current episode.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
178 participants (actual)

Groups and cohorts

  • Intussusception cohort

    Subjects with Intussusception

    Other: Screening sheets

Interventions

  • OtherScreening sheets

    Reviewing screening sheets

06

What researchers measure

Primary outcomes

  1. Occurrence of definite, probable and possible IS cases in children < 5 yrs of age

    Time frame: Average timeframe: one year

07

Study locations

5 sites
  • GSK Investigational Site
    Singapore, 119074, Singapore
  • GSK Investigational Site
    Singapore, 169608, Singapore
  • GSK Investigational Site
    Singapore, 228510, Singapore
  • GSK Investigational Site
    Singapore, 229899, Singapore
  • GSK Investigational Site
    Singapore, Singapore
08

References and documents

Publications

  • Phua KB, Lee BW, Quak SH, Jacobsen A, Teo H, Vadivelu-Pechai K, Gopala K, Liu Y. Incidence of intussusception in Singaporean children aged less than 2 years: a hospital-based prospective study. BMC Pediatr. 2013 Oct 8;13:161. doi: 10.1186/1471-2431-13-161. PubMed 24103115 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2002, a primary completion of Jul 2010 and a completion of Jul 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 6, 2010
First posted
Aug 9, 2010
Start
May 2002
Primary completionActual
Jul 2010
CompletionActual
Jul 2010
Last update
Nov 22, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 22, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01177839
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Aug 9, 2010
Start date
May 2002
Primary completion
Jul 2010
Completion
Jul 2010
Last update
Nov 22, 2012

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion